Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sedation may ease risky lung exam in breathless patients

NCT ID NCT00741949

Symptom relief Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving propofol sedation during a lung exam (bronchoscopy) under noninvasive ventilation helps patients with severe breathing failure stay more comfortable and maintain oxygen levels. Forty-six adults with acute respiratory failure needing a diagnostic lung exam took part. Half received propofol sedation, half received a placebo, and researchers measured oxygen saturation, patient comfort, and procedure success.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Propofol
What this could lead to
If it works, this could make bronchoscopy safer and more comfortable for patients with severe breathing problems, reducing the need for a breathing tube.
What could go wrong
This is a small, completed Phase 3 trial with only 46 participants, so results may not apply broadly. Propofol sedation can lower blood pressure or slow breathing, which could be risky in these patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Sep 2008

Finished

Jun 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Acute respiratory failure defined by clinical signs of respiratory failure (polypnea, use of accessory respiratory muscle) and a PaO2/FiO2 ratio \< 250 * Need for a diagnosis FOB with BAL * Informed consent signed Exclusion Criteria: * Contraindication of NIV * FOB with bronchial biopsies * Acute coronary syndrome * Thrombopenia \< 30.000 / mm3 despite platelets transfusion * Coagulation disorders * PaO2/FiO2 ratio \< 80 under NIV * Persistent respiratory acidosis under NIV (pH \< 7,32) * Propofol allergy * Xylocaïne allergy * Pregnancy * Age \< 18 years or \> 90 years * Weight \> 150 kg or \< 30 kg * Inclusion in another clinical protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute hypoxemic respiratory failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute respiratory failure respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Respiratory insufficiency

Contacts and locations

Locations

  • Centre hospitalier Libourne

    Libourne, 33505, France

  • University Hospital Bordeaux, Groupe Hospitalier Pellegrin

    Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.